title: [Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults].
abstract: Actually, allogeneic hematopoietic stem cell transplantation (AHSCT) is the treatment of choice of malignant hemopathies and also benign hemopathies. AHSCT conditioning presented three main objectives: anti-tumoral effect, immunosuppression and recipient bone marrow elimination. The standard conditioning is homogeneous in intensity but is unfortunately linked to an important toxicity and remains therefore reserved only to young patients. Better understanding of anti-tumoral mechanisms lead to the appearance of non-myeloablative conditioning or reduced intensity conditioning. The reduced intensity conditioning presented a great diversity (lower dose chemotherapy +/- total body irradiation). Many studies showed feasibility, tolerance and efficacy of this type of conditioning. However, this day, none of this conditioning showed his superiority in comparison with the others. Toxicity reduction provides an opportunity to use this approach in more and more old populations who were contraindicated to AHSCT with myeloablative conditioning.
authors.affiliation: Service d'hématologie greffe, hôpital Saint-Louis, 1 avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Peffault de Latour
authors.forename: Aurélie
authors.initials: A
authors.lastname: Cabrespine-Faugeras
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
mesh_terms: D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods / Q000639:trends*; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D007166:Immunosuppressive Agents